UVA Licensing & Ventures Group

Nanochon is focused on creating innovative implantable medical devices designed to address cartilage damage in joints. Utilizing advanced 3D printing techniques and a unique nanomaterial, the company aims to develop solutions that not only replace lost and damaged cartilage but also promote the growth of new tissue. This approach allows medical practitioners to access cost-effective and on-demand devices that enhance treatment outcomes, particularly for young and active patients suffering from knee injuries and diseases. Through its technology, Nanochon seeks to improve the overall quality of care in orthopedics.

LabBrightSpec addresses high-value, time-sensitive analytical chemistry challenges that are not well addressed by other spectroscopy techniques and instruments. It provides innovative laboratory services in order to deliver immediate results to potential customers of our instrumentation products. They are based in Charlottesville, Virginia, about two hours from Washington, DC. The BrightSpec Fourier transform molecular rotational resonance (FT-MRR) product platform is based on technology developed at the University of Virginia by Brooks Pate and his team, several of whom now work at BrightSpec. They offer FT-MRR product configurations for analytical chemistry and gas sensing in manufacturing process control, quality control, environmental monitoring, and formulation research.

Utrain is a developer of basketball training software that offers an all-in-one business management solution for basketball trainers. The platform serves as a secure marketplace, connecting athletes and parents with trainers, making it easy to find training services anytime and anywhere. Utrain enables trainers to present themselves to a broad community of aspiring athletes, fostering opportunities for athletes to enhance their skills while allowing trainers to broaden their clientele.

GenEp, Inc. is a pre-clinical stage biotechnology company focused on developing therapies for rare genetic epilepsies and other treatment-resistant epilepsies. The company utilizes its intellectual property to create selective compounds that modulate sodium and other ion channels, addressing mutations that contribute to these conditions. By targeting the specific genetic mutations responsible for treatment resistance, GenEp aims to enable medical professionals to provide more effective therapeutic options for patients suffering from these challenging disorders.

Nanochon is focused on creating innovative implantable medical devices designed to address cartilage damage in joints. Utilizing advanced 3D printing techniques and a unique nanomaterial, the company aims to develop solutions that not only replace lost and damaged cartilage but also promote the growth of new tissue. This approach allows medical practitioners to access cost-effective and on-demand devices that enhance treatment outcomes, particularly for young and active patients suffering from knee injuries and diseases. Through its technology, Nanochon seeks to improve the overall quality of care in orthopedics.

Mission Secure®, an OT cybersecurity leader, is setting a new standard in OT cyber-protection stopping OT cyber threats head-on. The Mission Secure Platform backed by 24/7 Managed Services is the first to seamlessly integrate OT visibility, segmentation, protection, threat hunting, and incident response, delivering military strength, industrial grade OT protection. With Mission Secure, customers keep critical operations up and running and safe from harm. Learn more at https://www.missionsecure.com.

Slate Bio is a company focused on developing immunotherapeutics aimed at treating autoimmune and inflammatory diseases. It creates therapies that leverage a bifunctional cytokine to restore the body's natural immunological response. By inducing antigen expression in genes associated with autoimmune conditions, Slate Bio offers a unique approach that provides patients with an independent synergistic pathway. This method is designed to enhance tissue selectivity and improve pharmacodynamics while minimizing the required dosage and potential side effects.

LabBrightSpec addresses high-value, time-sensitive analytical chemistry challenges that are not well addressed by other spectroscopy techniques and instruments. It provides innovative laboratory services in order to deliver immediate results to potential customers of our instrumentation products. They are based in Charlottesville, Virginia, about two hours from Washington, DC. The BrightSpec Fourier transform molecular rotational resonance (FT-MRR) product platform is based on technology developed at the University of Virginia by Brooks Pate and his team, several of whom now work at BrightSpec. They offer FT-MRR product configurations for analytical chemistry and gas sensing in manufacturing process control, quality control, environmental monitoring, and formulation research.

Merand Pharmaceuticals develops a microRNA therapeutic to treat Peripheral Arterial Disease. Merand's therapeutic treats patients by promoting angiogenesis or the development of new blood vessels, which leads to restored blood flow, enabling doctors to stabilize functional blood vessels of patients to increase perfusion recovery and reduce inflammation.

Direct Spinal Therapeutics, Inc. operates in the healthcare industry focusing on biotechnology business. The company was incorporated in 2013 and is based in Charlottesville, Virginia.

Arrive Health, founded in 2013 and based in Denver, Colorado, focuses on enhancing access to affordable, quality healthcare by providing precise, patient-specific cost and coverage information. The company develops integrated technologies that streamline workflows within health systems, facilitating conversations about affordability and access. By connecting a network of payers, pharmacy benefit managers, IT vendors, and other tools, Arrive Health alerts providers and care teams to coverage restrictions, lower-cost alternatives, and location-based options. This enables healthcare professionals to make well-informed decisions, ultimately reducing barriers throughout the care continuum.

Mission Secure®, an OT cybersecurity leader, is setting a new standard in OT cyber-protection stopping OT cyber threats head-on. The Mission Secure Platform backed by 24/7 Managed Services is the first to seamlessly integrate OT visibility, segmentation, protection, threat hunting, and incident response, delivering military strength, industrial grade OT protection. With Mission Secure, customers keep critical operations up and running and safe from harm. Learn more at https://www.missionsecure.com.

510 Kardiac Devices provides novel cardiovascular devices intended to assist in cardiovascular surgical procedures. Their intuitive platform provides physicians with an increased level of device control, functionality, and visibility. These features will make transseptal punctures more effective and efficient to perform and minimize costly complications. 510 Kardiac Devices is headquartered in Mableton, Georgia.

TearSolutions, Inc. is a biotechnology company based in Charlottesville, Virginia, focused on developing innovative therapies for dry eye conditions. Founded in 2013, the company is advancing Lacripep, a synthetic peptide derived from the natural tear protein lacritin, aimed at treating dry eyes, particularly in patients with primary Sjögren's syndrome. Lacripep is designed to preserve the biological activity of natural tear components while promoting healing of the corneal surface and alleviating symptoms without irritation. Currently, the company is conducting phase II human clinical trials to further validate its approach. TearSolutions employs an outsourcing model for its operations, emphasizing efficiency and scalability in the development and production of its therapies.

TypeZero Technologies LLC is focused on developing inControl, a comprehensive diabetes management platform aimed at improving the quality of life for individuals with diabetes. The platform includes a smartphone-based artificial pancreas solution that automates insulin delivery, significantly reduces the risk of hypoglycemia, and enhances blood glucose control. Additionally, inControl Advice provides real-time recommendations for meal planning, basal rates, bolus calculations, and exercise, while inControl Cloud offers tools for caregivers and family members to monitor patients and analyze data for potential treatment inefficiencies. With over a decade of clinical trials and research backing its innovations, TypeZero aims to deliver personalized diabetes management solutions that empower users to effectively manage their condition. The company, established in 2013 and located in Charlottesville, Virginia, operates as a subsidiary of DexCom, Inc. since August 2018.